Abstract: Antibodies, humanized antibodies, resurfaced antibodies, antibody fragments, derivatized antibodies, and conjugates of same with cytotoxic agents, which specifically bind to CD38, are capable of killing CD38+ cells by apoptosis, antibody-dependent cell-mediated cytotoxicity (ADCC), and/or complement-dependent cytotoxicity (CDC). Said antibodies and fragments thereof may be used in the treatment of tumors that express CD38 protein, such as multiple myeloma, chronic lymphocytic leukemia, chronic myelogenous leukemia, acute myelogenous leukemia, or acute lymphocytic leukemia, or the treatment of autoimmune and inflammatory diseases such as systemic lupus, rheumatoid arthritis, multiple sclerosis, erythematosus, and asthma. Said derivatized antibodies may be used in the diagnosis and imaging of tumors that express elevated levels of CD38.

Abstract: Novel polypeptides having anti-apoptotic activity, and methods of screening for such novel polypeptides having anti-apoptotic activity, and polynucleotides encoding such polypeptides; Compounds that regulate or modulate apoptosis and/or anti-apoptotic activity, such as compounds having anti-apoptotic activity, and such as compounds that induce, restore, or modulate apoptosis and/or inhibit, diminish, or modulate anti-apoptotic activity, methods of screening for such compounds, and methods of using such compounds in the therapeutic treatment of diseases; Methods of treating eukaryotic cells with compounds that regulate or modulate apoptosis and/or anti-apoptotic activity; Methods of enhancing the stability, growth, and/or productivity of eukaryotic cells; Pharmaceutical compositions that regulate or modulate apoptosis and/or anti-apoptotic activity.

Abstract: Disclosed are compositions and methods of screening for targets for antiviral chemotherapy having anti-apoptotic activity, and compositions and methods of screening for antiviral compounds that interfere with the anti-apoptotic activity of such targets. The targets comprise viral polypeptides having anti-apoptotic activity, and polynucleotides encoding such polypeptides. An example of such targets is a group of viral polypeptides of human cytomegalovirus (HCMV) having anti-apoptotic activity, such as pUL36, pUL37S, and pUL37L, and the polynucleotides encoding such polypeptides. The antiviral compounds comprise polypeptide, polynucleotide, DNA, RNA, amino acid, nucleic acid, and chemical compositions, including the chemically modified forms of such compositions, that interfere with the anti-apoptotic function of the target polypeptides and polynucleotides, leading to the induction of apoptosis and, consequently, the prevention or inhibition of replication.